检索
AI 对话
AI 写作
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

Atsushi Natsume,Yoshiki Arakawa,Yoshitaka Narita,Kazuhiko Sugiyama,Nobuhiro Hata,Yoshihiro Muragaki,Naoki Shinojima,Toshihiro Kumabe,Ryuta Saito,Kazuya Motomura,Yohei Mineharu,Yasuji Miyakita,Fumiyuki Yamasaki,Yuko Matsushita,Koichi Ichimura,Kazumi Ito,Masaya Tachibana,Yasuyuki Kakurai, Naoko Okamoto,Takashi Asahi,Soichiro Nishijima,Tomoyuki Yamaguchi,Hiroshi Tsubouchi,Hideo Nakamura,Ryo Nishikawa

Neuro-oncology（2023）

引用 15|浏览31
暂无评分
摘要
DS-1001 was well tolerated with a favorable brain distribution. Recurrent/progressive IDH1-mutant glioma patients responded to treatment. A study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 glioma is ongoing (NCT04458272).
更多
查看译文
关键词
D-2-HG,DS-1001,IDH1-mutant gliomas,brain,lower-grade glioma,penetrant selective IDH1 inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要